

Wei Qiu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1482024/publications.pdf>

Version: 2024-02-01

21
papers

749
citations

623734

14
h-index

752698

20
g-index

21
all docs

21
docs citations

21
times ranked

1304
citing authors

#	ARTICLE	IF	CITATIONS
1	PUMA Regulates Intestinal Progenitor Cell Radiosensitivity and Gastrointestinal Syndrome. <i>Cell Stem Cell</i> , 2008, 2, 576-583.	11.1	199
2	Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 20027-20032.	7.1	93
3	PUMA-mediated apoptosis drives chemical hepatocarcinogenesis in mice. <i>Hepatology</i> , 2011, 54, 1249-1258.	7.3	78
4	FAK Is required for c-Met/ β -catenin-driven hepatocarcinogenesis. <i>Hepatology</i> , 2015, 61, 214-226.	7.3	66
5	Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation. <i>Journal of Hepatology</i> , 2021, 75, 888-899.	3.7	45
6	Focal Adhesion Kinase and β -Catenin Cooperate to Induce Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 70, 1631-1645.	7.3	38
7	Inhibition of SIRT2 suppresses hepatic fibrosis. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, G1155-G1168.	3.4	35
8	Caspase-3 suppresses diethylnitrosamine-induced hepatocyte death, compensatory proliferation and hepatocarcinogenesis through inhibiting p38 activation. <i>Cell Death and Disease</i> , 2018, 9, 558.	6.3	28
9	Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling. <i>Cell Reports</i> , 2021, 34, 108765.	6.4	25
10	BID mediates selective killing of APC-deficient cells in intestinal tumor suppression by nonsteroidal antiinflammatory drugs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 16520-16525.	7.1	24
11	ABL1, Overexpressed in Hepatocellular Carcinomas, Regulates Expression of NOTCH1 and Promotes Development of Liver Tumors in Mice. <i>Gastroenterology</i> , 2020, 159, 289-305.e16.	1.3	22
12	Inhibition of insulin-like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival. <i>Hepatology Communications</i> , 2018, 2, 732-746.	4.3	21
13	Integrin subunit beta 8 contributes to lenvatinib resistance in HCC. <i>Hepatology Communications</i> , 2022, 6, 1786-1802.	4.3	18
14	FAK Kinase Activity Is Required for the Progression of c-MET/ β -Catenin-Driven Hepatocellular Carcinoma. <i>Gene Expression</i> , 2016, 17, 79-88.	1.2	16
15	Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma. <i>Cancer Research</i> , 2020, 80, 4224-4232.	0.9	12
16	FAK deletion accelerates liver regeneration after two-thirds partial hepatectomy. <i>Scientific Reports</i> , 2016, 6, 34316.	3.3	10
17	Focal Adhesion Kinase Promotes Hepatic Stellate Cell Activation by Regulating Plasma Membrane Localization of TGF β 2 Receptor 2. <i>Hepatology Communications</i> , 2020, 4, 268-283.	4.3	8
18	ABL1 is Overexpressed and Activated in Hepatocellular Carcinoma. <i>Journal of Cancer and Tumor International</i> , 2017, 6, 1-8.	0.1	5

#	ARTICLE	IF	CITATIONS
19	EPHA2, a promising therapeutic target for hepatocellular carcinoma. <i>Molecular and Cellular Oncology</i> , 2021, 8, 1910009.	0.7	3
20	Novel oncogenes and tumor suppressor genes in hepatocellular carcinoma. <i>Liver Research</i> , 2021, 5, 195-203.	1.4	3
21	REPLY:. <i>Hepatology</i> , 2019, 70, 1495-1496.	7.3	0